Arovella Therapeutics Ltd (ASX:ALA) CEO Michael Baker joins Jonathan Jackson in the Proactive studio to discuss a new, exclusive licensing agreement signed with the University of North Carolina Lineberger Comprehensive Cancer Center to incorporate a novel armouring cytokine technology (IL-12-TM) into its CAR-iNKT cell therapy platform. Baker discusses how this agreement enhances the company’s solid tumour pipeline and what the benefits will be. He also gives background into the CAR-iNKT cell therapy platform and the cytokine technology being developed and how the two will integrate and explains what it means to be developing an an off the shelf solution for cancer treatment. Finally, he explains what’s next for the company and what investors can expect in the months ahead.
Arovella Therapeutics to enhance solid tumour pipeline with exclusive licensing agreement
